Therefore, predictive biomarkers for CPI efficacy are largely related to tumor immunogenicity, such as tumor mutational burden [4], neoantigen burden [5], PD-L1 positivity [6], tumor-infiltrating lymphocytes [7], and IFN-γ gene signature [8]. The gene discussed is CD274; the disease is neoplasm.